Arrowhead Pharmaceuticals, Inc.
58.02USD
-0.3400 (-0.58%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on ARWR.
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 243.2M | 240.7M | 3.6M | 829.4M | 464.1M | 328.2M |
| Q1 | 27.4M | 62.5M | 3.6M | 2.5M | 264.0M | 45.8M |
| Q2 | 151.8M | 146.3M | 0.0 | 542.7M | 73.7M | — |
| Q3 | 32.4M | 15.8M | 0.0 | 27.8M | 75.3M | — |
| Q4 | 31.6M* | 16.1M* | 0.0* | 256.5M* | 60.4M | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | -1.67 | -1.92 | -5.00 | -.010 | -3.51 | -4.98 |
| Q1 | -.600 | -.390 | -1.24 | -1.39 | .220 | -1.37 |
| Q2 | .410 | .450 | -1.02 | 2.75 | -.930 | — |
| Q3 | -.680 | -.960 | -1.38 | -1.26 | -1.36 | — |
| Q4 | -.811* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
| -1.03* |
| -1.42* |
| -.178* |
| -1.50 |
| — |
Debt level and coverage